Lowenstein Sandler represented issuer Celldex Therapeutics, Inc. (Celldex) (Nasdaq: CLDX) in connection with the company’s approximately $150 million public offering of common stock underwritten by Cantor Fitzgerald & Co. as sole book-running manager and H.C. Wainwright & Co. acting as co-manager for the offering.
Celldex is a biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics.
About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.